Daily Stock Analysis, CYCC, Cyclacel Pharmaceuticals Inc, priceseries

Cyclacel Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.55
Close
0.53
High
0.55
Low
0.52
Previous Close
0.53
Daily Price Gain
0.00
YTD High
1.18
YTD High Date
Mar 25, 2019
YTD Low
0.52
YTD Low Date
Jun 12, 2019
YTD Price Change
-0.16
YTD Gain
-23.52%
52 Week High
1.87
52 Week High Date
Sep 5, 2018
52 Week Low
0.51
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-0.97
52 Week Gain
-64.67%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 31. 2017
3.68
Apr 13. 2017
5.91
9 Trading Days
60.53%
Link
LONG
Sep 12. 2017
1.88
Sep 13. 2017
2.00
1 Trading Days
6.65%
Link
LONG
Nov 15. 2017
1.68
Nov 29. 2017
1.83
9 Trading Days
8.99%
Link
LONG
Sep 4. 2018
1.57
Sep 5. 2018
1.72
1 Trading Days
9.55%
Link
Company Information
Stock Symbol
CYCC
Exchange
NasdaqCM
Company URL
http://www.cyclacel.com
Company Phone
908-517-7330
CEO
Spiro Rombotis
Headquarters
New Jersey
Business Address
200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ 07922
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001130166
About

Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders. Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism. It also develops Seliciclib and CYC065-Second Generation CDK Inhibitor. The company was founded by Ronald J. Berenson, David Philip Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Description

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.